Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2003;23:630-636
Published online before print January 23, 2003, doi: 10.1161/01.ATV.0000057808.91263.A4
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
23/4/630    most recent
01.ATV.0000057808.91263.A4v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Oksjoki, R.
Right arrow Articles by Pentikäinen, M. O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Oksjoki, R.
Right arrow Articles by Pentikäinen, M. O.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Related Collections
Right arrow Catheter-based coronary and valvular interventions: other
Right arrow Coagulation and fibronolysis
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2003;23:630.)
© 2003 American Heart Association, Inc.


Atherosclerosis and Lipoproteins

Association Between Complement Factor H and Proteoglycans in Early Human Coronary Atherosclerotic Lesions

Implications for Local Regulation of Complement Activation

Riina Oksjoki; Hanna Jarva; Petri T. Kovanen; Petri Laine; Seppo Meri; Markku O. Pentikäinen

From the Wihuri Research Institute (R.O., P.T.K., P.L., M.O.P.) and the Department of Bacteriology and Immunology, University of Helsinki, and Helsinki University Central Hospital (H.J., S.M.) Helsinki, Finland.

Correspondence to Petri T. Kovanen, MD, Wihuri Research Institute, Kalliolinnantie 4, FIN-00140 Helsinki, Finland. E-mail petri.kovanen{at}wri.fi

Objective— Complement activation has been suggested to play a role in atherogenesis. To study the regulation of complement activation in human coronary atherosclerotic lesions, we examined the spatial relationships between the major complement inhibitor, factor H, and the complement activation products C3d and C5b-9.

Methods and Results— In early lesions (American Heart Association types II and III), factor H was immunohistochemically found in the superficial proteoglycan-rich layer in association with numerous macrophages and C3d, whereas C5b-9 was found deeper in the intima, where factor H was virtually absent. In vitro experiments involving surface plasmon resonance and affinity chromatography analyses demonstrated that isolated human arterial proteoglycans bind factor H, and functional complement assays showed that glycosaminoglycans inhibit the complement activation induced by modified low density lipoprotein or by a foreign surface.

Conclusions— The present observations raise the possibility that proteoglycans, because of their ability to bind the major complement inhibitor factor H, may inhibit complement activation in the superficial layer of the arterial intima. In contrast, deeper in the intima, where factor H and proteoglycans are absent, complement may be activated and proceed to C5b-9. Thus, the superficial and the deep layers of the human coronary artery appear to differ in their ability to regulate complement activation.


Key Words: atherosclerosis • complement • factor H • proteoglycans




This article has been cited by other articles:


Home page
Am. J. Pathol.Home page
V. W.Y. Leung, S. Yun, M. Botto, J. C. Mason, T. H. Malik, W. Song, D. Paixao-Cavalcante, M. C. Pickering, J. J. Boyle, and D. O. Haskard
Decay-Accelerating Factor Suppresses Complement C3 Activation and Retards Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient Mice
Am. J. Pathol., October 1, 2009; 175(4): 1757 - 1767.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
K. C.M.C. Koeijvoets, S. P. Mooijaart, G. M. Dallinga-Thie, J. C. Defesche, E. W. Steyerberg, R. G.J. Westendorp, J. J.P. Kastelein, P. M. van Hagen, and E. J.G. Sijbrands
Complement factor H Y402H decreases cardiovascular disease risk in patients with familial hypercholesterolaemia
Eur. Heart J., March 1, 2009; 30(5): 618 - 623.
[Abstract] [Full Text] [PDF]


Home page
Arch OphthalmolHome page
S. S. Boekhoorn, J. R. Vingerling, J. C. M. Witteman, A. Hofman, and P. T. V. M. de Jong
C-reactive Protein Level and Risk of Aging Macula Disorder: The Rotterdam Study
Arch Ophthalmol, October 1, 2007; 125(10): 1396 - 1401.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
F. J. de Jong, M. K. Ikram, D. D. G. Despriet, A. G. Uitterlinden, A. Hofman, M. M. B. Breteler, and P. T. V. M. de Jong
Complement Factor H Polymorphism, Inflammatory Mediators, and Retinal Vessel Diameters: The Rotterdam Study
Invest. Ophthalmol. Vis. Sci., July 1, 2007; 48(7): 3014 - 3018.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
J. K. Pai, J. E. Manson, K. M. Rexrode, C. M. Albert, D. J. Hunter, and E. B. Rimm
Complement factor H (Y402H) polymorphism and risk of coronary heart disease in US men and women
Eur. Heart J., June 1, 2007; 28(11): 1297 - 1303.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
V. K. Bhatia, S. Yun, V. Leung, D. C. Grimsditch, G. M. Benson, M. B. Botto, J. J. Boyle, and D. O. Haskard
Complement C1q Reduces Early Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient Mice
Am. J. Pathol., January 1, 2007; 170(1): 416 - 426.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
T. T. Keller, S. I. van Leuven, M. C. Meuwese, N. J. Wareham, R. Luben, E. S. Stroes, C. E. Hack, M. Levi, K.-T. Khaw, and S. M. Boekholdt
Serum Levels of Mannose-Binding Lectin and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women
Arterioscler Thromb Vasc Biol, October 1, 2006; 26(10): 2345 - 2350.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
I. Kardys, C. C.W. Klaver, D. D.G. Despriet, A. A.B. Bergen, A. G. Uitterlinden, A. Hofman, B. A. Oostra, C. M. Van Duijn, P. T.V.M. de Jong, and J. C.M. Witteman
A Common Polymorphism in the Complement Factor H Gene Is Associated With Increased Risk of Myocardial Infarction: The Rotterdam Study
J. Am. Coll. Cardiol., April 18, 2006; 47(8): 1568 - 1575.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
R. Oksjoki, P. T. Kovanen, K. A. Lindstedt, B. Jansson, and M. O. Pentikainen
OxLDL-IgG Immune Complexes Induce Survival of Human Monocytes
Arterioscler Thromb Vasc Biol, March 1, 2006; 26(3): 576 - 583.
[Abstract] [Full Text] [PDF]


Home page
ScienceHome page
J. L. Haines, M. A. Hauser, S. Schmidt, W. K. Scott, L. M. Olson, P. Gallins, K. L. Spencer, S. Y. Kwan, M. Noureddine, J. R. Gilbert, et al.
Complement Factor H Variant Increases the Risk of Age-Related Macular Degeneration
Science, April 15, 2005; 308(5720): 419 - 421.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
G. Camejo
Hydrolytic Enzymes Released From Resident Macrophages and Located in the Intima Extracellular Matrix as Agents That Modify Retained Apolipoprotein B Lipoproteins
Arterioscler Thromb Vasc Biol, August 1, 2003; 23(8): 1312 - 1313.
[Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
H. Rus and F. Niculescu
Association of Complement Inhibitors With Connective Tissue Matrix in Atherosclerotic Lesions
Arterioscler Thromb Vasc Biol, August 1, 2003; 23(8): 1478 - 1478.
[Full Text] [PDF]